Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer.
Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer.
复制标题
DOI:
10.1097/aog.0000000000000240
复制
发表时间:
2014-05
影响因子:
7.2
通讯作者:
Sood AK
中科院分区:
文献类型:
--
作者:
Matsuo K;Yoshino K;Hiramatsu K;Banzai C;Hasegawa K;Yasuda M;Nishimura M;Sheridan TB;Ikeda Y;Shiki Y;Mabuchi S;Enomoto T;Kimura T;Fujiwara K;Roman LD;Sood AK
To evaluate the effect of lymphovascular space invasion on survival of early-stage epithelial ovarian cancer patients. A multicenter retrospective study was conducted for patients with stage IA-C epithelial ovarian cancer who underwent primary comprehensive surgery including lymphadenectomy. Histopathology slides for ovarian tumors were examined by gynecologic pathologists for presence or absence of lymphovascular space invasion. Survival analysis was performed examining tumoral factors. A total of 434 cases were included in the analysis. Lymphovascular space invasion was detected in 76 (17.5%) cases, associated with histology (p=0.042) and stage (p=0.044). Lymphovascular space invasion was significantly associated with decreased survival outcomes (disease-free survival [DFS], 5-year rate 78.4% versus 90.7%, p=0.024, and overall survival [OS], 84.9% versus 93.2%, p=0.031) in univariate analysis. In multivariate analysis, lymphovascular space invasion did not remain a significant variable for DFS (hazard ratio [HR] 1.98, 95%CI 0.97-3.97, p=0.059) or OS (HR 2.41, 95%CI 0.99-5.85, p=0.052). Lymphovascular space invasion was associated with increased risk of hematogenous and lymphatic metastasis (HR 4.79, 95%CI 1.75-13.2, p=0.002) but not peritoneal metastasis (p=0.33) in multivariate analysis. Among lymphovascular space invasion-expressing tumors, patients who received fewer than 6 cycles of postoperative chemotherapy had significantly poorer DFS than those who received six or more cycles (HR 4.59, 95%CI 1.20-17.5, p=0.015). Lymphovascular space invasion is an important histological feature to identify a subgroup of patients with increased risk of recurrence in stage I epithelial ovarian cancer.